Sanofi

SAN

FR0000120578

Pharmaceuticals

Real-time Euronext Paris Other stock markets 06:27:12 16/06/2026 pm IST			5-day change	1st Jan Change
75.62 ^EUR	+0.11%		-1.90%	-8.63%

15/06	European Equities Traded in the US as American Depositary Receipts Surge in Monday Trading	MT
15/06	Global drugmakers invest billions to boost US presence	RE

Sanofi: Quarterly beat is fine, but longer-term growth prospects remain questionable

Published on 04/23/2026 at 10:05 pm IST

Alphavalue

Sanofi: Quarterly beat is fine, but longer-term growth prospects remain questionable

This article is reserved for subscribers.

Alphavalue, the European leader in independent research, is exclusively available on MarketScreener.

To unlock the article, subscribe!

Latest news about Sanofi

15/06	European Equities Traded in the US as American Depositary Receipts Surge in Monday Trading	MT
15/06	Global drugmakers invest billions to boost US presence	RE
15/06	Sanofi Says US FDA Approved Tzield for Recently Diagnosed Stage 3 Type 1 Diabetes in Children	MT
15/06	SANOFI : Gets a Buy rating from Deutsche Bank	ZD
15/06	Sanofi Secures Accelerated Approval in Diabetes
15/06	Sanofi Wins US Approval for Disease-modifying Therapy for Diabetes in Children	MT
13/06	Sanofi - Shareholder/Analyst Call
13/06	Sanofi Receives Accelerated Approval for Tzield as First Disease-Modifying Therapy for Stage 3 Type 1 Diabetes	CI
13/06	FDA approves expanded use of Sanofi's type 1 diabetes drug	RE
13/06	FDA approves Sanofi's drug for stage 3 type 1 diabetes in children	RE
13/06	Sanofi's Tzield Receives FDA Approval for Diabetes Treatment	DJ
10/06	European Stocks Close Mixed in Wednesday Trading; Bank, Automotive Stocks Slump	MT
10/06	European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	MT
10/06	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday Amid Renewed US-Iran Clashes	MT
10/06	CIC Corp. & Institutional Banking Trims Sanofi PT, Keeps Buy Rating	MT

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).

Employees

74,846

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company